Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Chung Shan Medical University
  3. Pure學術人才庫轉入
  4. Effects of SGLT2 inhibitors on transplant survival and key clinical outcomes in heart transplant recipients with diabetes
 
  • Details
Options

Effects of SGLT2 inhibitors on transplant survival and key clinical outcomes in heart transplant recipients with diabetes

Journal
Journal of Internal Medicine
Date Issued
2025-05-01
Author(s)
JING-YANG HUANG  
JAMES CHENG-CHUNG WEI  
DOI
10.1111/joim.20077
URI
https://www.scopus.com/pages/publications/85218701076
https://scholars.csmu.edu.tw/handle/123456789/25284
Abstract
Background: Chronic kidney disease and heart allograft vasculopathy are the primary causes of morbidity and mortality after cardiac transplant. This study aimed to evaluate the impact of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on transplant survival, cardiovascular events, dialysis, and all-cause mortality in diabetes patients who have undergone heart transplantation. Methods: In this research, we adopted data from the TriNetX collaborative network to observe outcomes in patients who underwent heart transplants between January 01, 2015 and December 31, 2022. A total of 6494 transplant recipients were identified, from which 1063 matched pairs of SGLT2i users and non-users were selected using propensity score matching. The Kaplan–Meier analysis and Cox proportional hazards models were applied to compare the risks of various outcomes between the study and control groups. Results: In propensity-matched cohorts, patients using SGLT2i exhibited a lower risk of dialysis [hazard ratio (HR) (95% confidence interval [CI]): 0.566 (0.385–0.833)], graft rejection and failure [0.873 (0.774–0.985)], hospitalizations [0.822 (0.739–0.916)], and all-cause death [0.767 (0.627–0.938)] compared to non-users. Yet, no significant differences were observed between the two groups in the risks of post-transplant infection or sepsis [0.891 (0.739–1.075)], ischemic heart disease (HR: 1.044, 95% CI: 0.939–1.161), and heart failure worsening [0.915 (0.733–1.144)]. Conclusion: This multicenter cohort study demonstrated that cardiac transplant recipients with diabetes who received SGLT2i had a significantly lower risk of dialysis, graft rejection, hospitalization, and all-cause mortality compared to those who did not receive SGLT2i.
Type
journal article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback